Metronomic therapy focused on cholinergic receptors to treat cancer. Are nicotinic receptors involved?

SALES M; ALEJANDRO ESPAÑOL; SALEM , A

Simposio; 2019 Non-neuronal Acetylcholine International Symposium: From Bench to Bedside; 2019

Cholinergic modulation of tumor progression has been described in different experimental models. In our laboratory, we demonstrated that long term treatment of murine mammary tumors with the non-selective agonist, carbachol (CARB) promotes cell death through the activation of muscarinic (M) receptors. We studied the effect of a combination of sub threshold doses of CARB (10-12M) with paclitaxel (PX) (10-8M) a cytotoxic agent used in the treatment of breast cancer, on MDA-MB231 cells derived from a human triple negative breast tumor. The combination of CARB+PX reduced cell viability by 27±3% (p